Answers are grounded in this paper and cite their sources.
Observational analysis reveals frequent HRR and PIK3CA mutations in ovarian cancer ascites, indicating valuable targets for personalized therapy.
This study evaluated immunohistochemical (IHC) markers and homologous recombination repair (HRR) gene mutations in 58 ovarian cancer patients using ascites-derived paraffin-embedded cell blocks. IHC analysis revealed high expression of Pax-8 (87.5–100%), WT-1 (87.8–90%), CA-125 (100%), and CK7 (100%) across subtypes, supporting their diagnostic utility. HRR gene mutations were detected in 77.6% of cases, with TP53 (55%) and PIK3CA (21.7%) as the most frequent alterations. Nine BRCA1/2 mutations were identified. PIK3CA variants included E545K (28.6%) and E542K (28.6%), suggesting potential therapeutic targets. These findings highlight the clinical relevance of ascites cell blocks for molecular profiling, with HRR status guiding PARP inhibitor therapy and PIK3CA mutations indicating PI3K/AKT pathway inhibition. This approach may optimize personalized treatment strategies for advanced ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: